Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences, Medical Universi-ty of Silesia, Upper Silesian Medical Center in Katowice, Polska.
Endocrinological Outpatient Clinic, Upper Silesian Medical Center in Katowice, Poland.
Pediatr Endocrinol Diabetes Metab. 2023;29(2):97-103. doi: 10.5114/pedm.2023.124266.
Subclinical hypothyroidism (SH) is a biochemical diagnosis made when a serum thyroid-stimulating hormone (TSH) is ele-vated with circulating thyroid hormone levels within their reference ranges.
Aim of our prospective non-randomized study was to evaluate the course of SH.
All patients with suspicion of SH referred to the Endocrinology Outpatient Clinic between 2014 and 2018 were recruited to prospective study.
A total of 130 patients with SH were recruited for this study. Thirty-five (26.9%) patients were followed up without levothy-roxine (L-T4) (SH-T0 group) and therapy with L-T4 was randomly introduced in 95/130 (73.1%) SH children (SH-T1 group). We did not find statistical differences in hSDS and BMI Z-score between the SH-T0 and SH-T1 groups (p = 0.761 and p = 0.843, respectively). Introducing L-T4 in patients with short stature did not affect the linear growth at the end of FU ex-pressed as hSDS. OH developed in six children (6.3%) in the SH-T1 group. After conducting a multivariate logistic regres-sion, we found that the baseline TSH concentration and BMI Z-score are possible predictors of OH.
Our study confirmed a low risk of progression of SH to overt hypothyroidism. The majority of patients remains SH or resolved for nor-mal thyroid function. The L-T4 therapy did not effect on linear growth and body weight. The main predictor of worsening to hypothyroidism were a higher TSH level and Z-score BMI.
亚临床甲状腺功能减退症(SH)是一种血清促甲状腺激素(TSH)升高而循环甲状腺激素水平在参考范围内的生化诊断。
本前瞻性非随机研究的目的是评估 SH 的病程。
2014 年至 2018 年间,所有疑似 SH 的患者均被招募至内分泌门诊进行前瞻性研究。
本研究共招募了 130 名 SH 患者。35 名(26.9%)患者未接受左甲状腺素(L-T4)治疗(SH-T0 组),95/130(73.1%)SH 儿童随机接受 L-T4 治疗(SH-T1 组)。我们未发现 SH-T0 组和 SH-T1 组之间的 hSDS 和 BMI Z 评分存在统计学差异(p=0.761 和 p=0.843)。在身材矮小的患者中引入 L-T4 并不会影响随访结束时的线性生长,表现为 hSDS。在 SH-T1 组中有 6 名儿童(6.3%)发生了 OH。进行多变量逻辑回归后,我们发现基线 TSH 浓度和 BMI Z 评分可能是 OH 的预测因素。
我们的研究证实 SH 向显性甲状腺功能减退症进展的风险较低。大多数患者仍为 SH 或甲状腺功能恢复正常。L-T4 治疗对线性生长和体重无影响。TSH 水平和 BMI Z 评分升高是甲状腺功能恶化的主要预测因素。